Factors influencing methotrexate and methotrexate polyglutamate in patients with rheumatoid arthritis: a systematic review of population pharmacokinetics

References

1. Fraenkel, L, Bathon, JM, England, BR, EW St Clair, Arayssi, T, Carandang, K, et al.. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2021;73:924–39. https://doi.org/10.1002/acr.24596.Search in Google Scholar PubMed PubMed Central

2. Brown, PM, Pratt, AG, Isaacs, JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 2016;12:731–42. https://doi.org/10.1038/nrrheum.2016.175.Search in Google Scholar PubMed

3. Visentin, M, Zhao, R, Goldman, ID. The antifolates. Hematol Oncol Clin N Am 2012;26:629–48. https://doi.org/10.1016/j.hoc.2012.02.002.Search in Google Scholar PubMed PubMed Central

4. Whittle, SL, Hughes, RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology 2004;43:267–71. https://doi.org/10.1093/rheumatology/keh088.Search in Google Scholar PubMed

5. Friedman, B, Cronstein, B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine 2019;86:301–7. https://doi.org/10.1016/j.jbspin.2018.07.004.Search in Google Scholar PubMed PubMed Central

6. Kaltsonoudis, E, Papagoras, C, Drosos, AA. Current and future role of methotrexate in the therapeutic armamentarium for rheumatoid arthritis. Int J Clin Rheumatol 2012;7:179. https://doi.org/10.2217/ijr.12.10.Search in Google Scholar

7. Visser, K, Katchamart, W, Loza, E, Martinez-Lopez, J, Salliot, C, Trudeau, J, et al.. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086–93. https://doi.org/10.1136/ard.2008.094474.Search in Google Scholar PubMed PubMed Central

8. Pichlmeier, U, Heuer, K-U. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol 2014;32:563–71.Search in Google Scholar

9. Desmoulin, SK, Hou, Z, Gangjee, A, Matherly, LH. The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol Ther 2012;13:1355–73. https://doi.org/10.4161/cbt.22020.Search in Google Scholar PubMed PubMed Central

10. Murakami, T, Mori, N. Involvement of multiple transporters-mediated transports in mizoribine and methotrexate pharmacokinetics. Pharmaceuticals 2012;5:802–36. https://doi.org/10.3390/ph5080802.Search in Google Scholar PubMed PubMed Central

11. Claudepierre, P, Urien, S, Chevalier, X, Chassany, O, Larget-Piet, B, Tillement, JP. Methotrexate serum binding in rheumatoid arthritis. Int J Clin Pharm Ther 1994;32:113–5.Search in Google Scholar

12. Bressolle, F, Bologna, C, Edno, L, Bernard, JC, Gomeni, R, Sany, J, et al.. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. Eur J Clin Pharmacol 1996;49:285–92. https://doi.org/10.1007/bf00226329.Search in Google Scholar PubMed

13. Bannwarth, B, Labat, L, Moride, Y, Schaeverbeke, T. Methotrexate in rheumatoid arthritis. An update. Drugs 1994;47:25–50. https://doi.org/10.2165/00003495-199447010-00003.Search in Google Scholar PubMed

14. Huerta-García, AP, Rodríguez-Báez, AS, Medellín-Garibay, SE, Portales-Pérez, DP, Martínez-Martínez, MU, Abud-Mendoza, C, et al.. Methotrexate triglutamate as a determinant of clinical response in Mexican patients with rheumatoid arthritis: pharmacokinetics and dose recommendation. J Clin Pharmacol 2021;61:1118–30.10.1002/jcph.1837Search in Google Scholar PubMed

15. Raz, S, Stark, M, Assaraf, YG. Folylpoly-γ-glutamate synthetase: a key determinant of folate homeostasis and antifolate resistance in cancer. Drug Resist Updates 2016;28:43–64. https://doi.org/10.1016/j.drup.2016.06.004.Search in Google Scholar PubMed

16. Muller, IB, Hebing, RF, Jansen, G, Nurmohamed, MT, Lems, WF, Peters, GJ, et al.. Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylation revisited. Expert Rev Precis Med Drug Dev 2018;3:331–4. https://doi.org/10.1080/23808993.2018.1517025.Search in Google Scholar

17. Seideman, P, Beck, O, Eksborg, S, Wennberg, M. The pharmacokinetics of methotrexate and its 7‐hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993;35:409–12. https://doi.org/10.1111/j.1365-2125.1993.tb04158.x.Search in Google Scholar PubMed PubMed Central

18. Bannwarth, B, Labat, L, Moride, Y, Schaeverbeke, T. Methotrexate in rheumatoid arthritis. Drugs 1994;47:25–50. https://doi.org/10.2165/00003495-199447010-00003.Search in Google Scholar PubMed

19. Nuernberg, B, Koehnke, R, Solsky, M, Hoffman, J, Furst, DE. Biliary elimination of low‐dose methotrexate in humans. Arthritis Rheum 1990;33:898–902. https://doi.org/10.1002/art.1780330620.Search in Google Scholar PubMed

20. Lafforgue, P, Monjanel-Mouterde, S, Durand, A, Catalin, J, Acquaviva, PC. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995;22:844–9.Search in Google Scholar

21. Stamp, LK, Barclay, M. Therapeutic drug monitoring in rheumatic diseases: utile or futile? Rheumatology 2014;53:988–97. https://doi.org/10.1093/rheumatology/ket355.Search in Google Scholar PubMed

22. Hobl, E-L, Jilma, B, Erlacher, L, Duhm, B, Mustak, M, Bröll, H, et al.. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol 2012;30:156.Search in Google Scholar

23. Hornung, N, Ellingsen, T, Attermann, J, Stengaard-Pedersen, K, Poulsen, JH. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol 2008;35:1709–15.Search in Google Scholar

24. Dervieux, T, Furst, D, Lein, DO, Capps, R, Smith, K, Walsh, M, et al.. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766–74. https://doi.org/10.1002/art.20460.Search in Google Scholar PubMed

25. Angelis-Stoforidis, P, Vajda, F, Christophidis, N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313–20.Search in Google Scholar

26. Becker, ML, Gaedigk, R, Van Haandel, L, Thomas, B, Lasky, A, Hoeltzel, M, et al.. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011;63:276–85. https://doi.org/10.1002/art.30080.Search in Google Scholar PubMed

27. Stamp, LK, O’Donnell, JL, Chapman, PT, Zhang, M, James, J, Frampton, C, et al.. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long‐term methotrexate therapy. Arthritis Rheum 2010;62:359–68. https://doi.org/10.1002/art.27201.Search in Google Scholar PubMed

28. Yukawa, E, Mori, S, Ueda, K, Nakada, Y. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients. J Clin Pharm Therapeut 2007;32:573–8. https://doi.org/10.1111/j.1365-2710.2007.00859.x.Search in Google Scholar PubMed

29. Godfrey, C, Sweeney, K, Miller, K, Hamilton, R, Kremer, J. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998;46:369–76. https://doi.org/10.1046/j.1365-2125.1998.t01-1-00790.x.Search in Google Scholar PubMed PubMed Central

30. Korell, J, Stamp, LK, Barclay, ML, Dalrymple, JM, Drake, J, Zhang, M, et al.. A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clin Pharmacokinet 2013;52:475–85. https://doi.org/10.1007/s40262-013-0052-y.Search in Google Scholar PubMed

31. Pan, S, Stamp, LK, Duffull, SB, Barclay, ML, Dalrymple, JM, Drake, J, et al.. Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet 2014;53:1161–70. https://doi.org/10.1007/s40262-014-0179-5.Search in Google Scholar PubMed

32. Herrick, AL, Grennan, DM, Griffen, K, Aarons, L, Gifford, LA. Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis. Br J Clin Pharmacol 1996;41:223–7. https://doi.org/10.1111/j.1365-2125.1996.tb00186.x.Search in Google Scholar PubMed

33. Wang, Z, Zhang, N, Chen, C, Chen, S, Xu, J, Zhou, Y, et al.. Influence of the OATP polymorphism on the population pharmacokinetics of methotrexate in Chinese patients. Curr Drug Metabol 2019;20:592–600. https://doi.org/10.2174/1389200220666190701094756.Search in Google Scholar PubMed PubMed Central

34. Stamp, L, Roberts, R, Kennedy, M, Barclay, M, O’Donnell, J, Chapman, P. The use of low dose methotrexate in rheumatoid arthritis—are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother 2006;60:678–87. https://doi.org/10.1016/j.biopha.2006.09.007.Search in Google Scholar PubMed

35. Wang, W, Zhou, H, Liu, L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem 2018;158:502–16. https://doi.org/10.1016/j.ejmech.2018.09.027.Search in Google Scholar PubMed

36. Dervieux, T, Furst, D, Lein, DO, Capps, R, Smith, K, Caldwell, J, et al.. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180–5. https://doi.org/10.1136/ard.2004.033399.Search in Google Scholar PubMed PubMed Central

37. Methaneethorn, J, Leelakanok, N. Sources of lamotrigine pharmacokinetic variability: a systematic review of population pharmacokinetic analyses. Seizure 2020;82:133–47.10.1016/j.seizure.2020.07.014Search in Google Scholar PubMed

38. Methaneethorn, J, Leelakanok, N. Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis. Eur J Clin Pharmacol 2021;77:291–309. https://doi.org/10.1007/s00228-020-03011-x.Search in Google Scholar PubMed

39. Methaneethorn, J, Leelakanok, N. Population pharmacokinetics of levetiracetam: a systematic review. Curr Clin Pharmacol 2021;16:1–13. https://doi.org/10.2174/1574884716666210223110658.Search in Google Scholar PubMed

40. Methaneethorn, J, Lohitnavy, M, Leelakanok, N. A systematic review of population pharmacokinetics of carbamazepine. Sys Rev Pharm 2020;11:653–73.Search in Google Scholar

41. König, J, Seithel, A, Gradhand, U, Fromm, MF. Pharmacogenomics of human OATP transporters. Naunyn-Schmiedeb Arch Pharmacol 2006;372:432–43. https://doi.org/10.1007/s00210-006-0040-y.Search in Google Scholar PubMed

42. Ijaz, S, Yang, W, Winslet, MC, Seifalian, AM. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003;10:447–56. https://doi.org/10.1038/sj.mn.7800206.Search in Google Scholar PubMed

43. Hanley, MJ, Abernethy, DR, Greenblatt, DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49:71–87. https://doi.org/10.2165/11318100-000000000-00000.Search in Google Scholar PubMed

44. Smit, C, De Hoogd, S, Brüggemann, RJM, Knibbe, CAJ. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expet Opin Drug Metabol Toxicol 2018;14:275–85. https://doi.org/10.1080/17425255.2018.1440287.Search in Google Scholar PubMed

45. Chumlea, WC, Guo, SS, Zeller, CM, Reo, NV, Baumgartner, RN, Garry, PJ, et al.. Total body water reference values and prediction equations for adults. Kidney Int 2001;59:2250–8. https://doi.org/10.1046/j.1523-1755.2001.0590062250.x.Search in Google Scholar

46. Chumlea, WC, Schubert, CM, Reo, NV, Sun, SS, Siervogel, RM. Total body water volume for white children and adolescents and anthropometric prediction equations: the Fels longitudinal study. Kidney Int 2005;68:2317–22. https://doi.org/10.1111/j.1523-1755.2005.00692.x.Search in Google Scholar PubMed

47. Pensomboon, P, Charoenwong, N, Towiwat, P, Sermsappasuk, P. Effect of the dosing interval for oral dosage regimens of methotrexate on the probability of target attainment in rheumatoid arthritis patients using Monte Carlo simulation. Thai J Pharmacol 2020;42:20–35.Search in Google Scholar